Skip to main content
Reimbursement strategy

Market Access Strategy for Medical Devices in Europe

Strategic recommendations on the topic of market access pathways for medical devices and IVD tests

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

List of medical procedures reimbursed with restrictions updated for 2026 in the Netherlands

On January 2, 2026, the Dutch Healthcare Institute (ZIN) published the updated list of medical procedures reimbursed under basic health insurance with restrictions or limitations. The procedures have the so-called "claim" codes (aanspraakcodes). The Dutch Healthcare Authority assigns the "claim" codes based on positions published by the ZIN. The implemented changes included the introduction of two procedure codes. All other changes are structural, editorial, or classificatory, with no impact on entitlements.

Two procedure codes 191179 ”Cryopreservation or thawing of own ovarian tissue for own use for a medical indication, including intake (optional) and examination” and 191180 “Storage of frozen own ovarian tissue for own use for a medical indication, per year” were included in the list with “claim” code 2605 “Fertility treatment.” 

See more information in Dutch here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.